


WHAT IS CLAIMED IS:

- 1 1. An amorphous form of Compound 1



(Compound 1)

- 2 characterized by an X-ray powder diffraction pattern having no distinct peaks, which is
3 substantially free of other forms of Compound 1.

- 1 2. The amorphous form of Compound 1 according to claim 1, characterized
2 by an X-ray powder diffraction pattern substantially in accordance with **FIG. 2**.

- 1 3. The amorphous form of Compound 1 according to claim 1 or claim 2,
2 further characterized by a glass transition temperature of about 108 °C, as determined by
3 differential scanning calorimetry.

- 1 4. The amorphous form of Compound 1 according to claim 1 or claim 2,
2 further characterized by a differential scanning calorimetry (DSC) thermogram substantially in
3 accordance with **FIG. 4**.

- 1 5. The amorphous form of Compound 1 according to any one of claims 1 to
2 4, further characterized by a weight loss of about 0.015% up heating to around 235 °C, as
3 measured by thermal gravimetric analysis (TGA).

- 1 6. The amorphous form of Compound 1 according to any one of claims 1 to
2 4, further characterized a thermal gravimetric analysis (TGA) thermogram substantially in
3 accordance with **FIG. 5**.

- 1 7. The amorphous form of Compound 1 according to any one of claims 1 to
2 6, further characterized by a weight gain of about 0.44% after undergoing a dynamic vapor
3 sorption (DVS) cycle from about 0% relative humidity (RH) to about 95% RH at 25 °C.

1 **8.** The amorphous form of Compound 1 according to any one of claims **1** to
2 **6**, further characterized by a weight gain of about 0.31% after undergoing a dynamic vapor
3 sorption (DVS) cycle from about 0% relative humidity (RH) to about 65% RH at 25 °C.

1 **9.** The amorphous form of Compound 1 according to any one of claims **1** to
2 **6**, further characterized by a dynamic vapor sorption (DVS) plot that does not exhibit any
3 hysteresis between adsorption and desorption.

1 **10.** The amorphous form of Compound 1 according to any one of claims **1** to
2 **6**, further characterized by a dynamic vapor sorption (DVS) plot substantially in accordance with
3 **FIG. 6**.

1 **11.** The amorphous form of Compound 1 according to any one of claims **1** to
2 **10**, further characterized by a scanning electron microscopy (SEM) image having predominantly
3 spherical particles.

1 **12.** The amorphous form of Compound 1 according to claim **11**, wherein
2 **spherical particle sizes are about 2 μm to 50 μm**, as determined by SEM.

1 **13.** The amorphous form of Compound 1 according to any one of claims **1** to
2 **10**, further characterized by scanning electron microscopy (SEM) image substantially in
3 accordance with FIG. 8A, FIG. 8B, FIG. 8C, or FIG. 8D.

1 **14.** The amorphous form of Compound 1 according to any one of claims **1** to
2 **13**, further characterized by a polarized light microscope (PLM) profile lacking birefringence.

1 **15.** The amorphous form of Compound 1 according to any one of claims **1** to
2 **13**, further characterized by a polarized light microscope (PLM) profile substantially as shown in
3 FIG. 9A, FIG. 9B, or FIG. 9C.

1 **16.** A process for preparing an amorphous form of Compound 1, the process
2 comprising

- 3 a) dissolving Compound 1 in a polar, aprotic solvent to form a solution;
4 b) spray drying the solution to form an amorphous form of Compound 1.

- 1 **17.** The process of claim **16**, wherein the polar, aprotic solvent is selected
2 from the group consisting of tetrahydrofuran (THF), acetone, dichloromethane (DCM), and
3 mixtures thereof.
- 1 **18.** The process of claim **16**, wherein the polar, aprotic solvent is THF.
- 1 **19.** The process of claim **16**, wherein the polar, aprotic solvent is acetone.
- 1 **20.** The process of claim **16**, wherein the polar, aprotic solvent is DCM.
- 1 **21.** A process for preparing an amorphous form of Compound 1, the process
2 comprising
3 a) dissolving Compound 1 in a polar, aprotic solvent to form a solution,
4 wherein the concentration of Compound 1 in the solution is no more than 0.3
5 g/mL;
6 b) optionally filtering the solution to form a filtrate; and
7 c) removing solvent from the solution or the filtrate to form an amorphous form of
8 Compound 1.
- 1 **22.** A pharmaceutical composition comprising the amorphous form of
2 Compound 1 according to any one of claims **1** to **15** and at least one pharmaceutically acceptable
3 excipient.
- 1 **23.** An aqueous suspension comprising the amorphous form of Compound 1
2 according to any one of claims **1** to **15** and at least one excipient.
- 1 **24.** The aqueous suspension of claim **23**, wherein the at least one excipient is
2 at least one suspending agent and/or at least one wetting agent.
- 1 **25.** The aqueous suspension of claim **23** or claim **24**, wherein the aqueous
2 suspension further comprises a sweetening agent.

1 **26.** An injectable or infusible solution comprising Compound 1 and at least
2 one wetting agent or solvent, wherein the injectable or infusible solution is prepared using the
3 amorphous form of Compound 1 according to any one of claims **1** to **15**.

1 **27.** The injectable or infusible solution of claim **26**, prepared for intravenous
2 administration.

1 **28.** The injectable or infusible solution of claim **26**, prepared for intramuscular
2 administration.

1 **29.** The injectable or infusible solution of claim **26**, prepared for subcutaneous
2 injection.

1 **30.** The injectable or infusible solution of any one of claims **26** to **29**, wherein
2 the injectable or infusible solution is prepared shortly before use by dissolving the amorphous
3 form of Compound 1 with the at least one wetting agent or solvent.

1 **31.** A method of using the injectable or infusible solution of any one of claims
2 **26** to **29**, comprising
3 dissolving the amorphous form of Compound 1 with the at least one wetting agent or
4 solvent to prepare an injectable or infusible solution; and
5 administering the injectable or infusible solution to a subject in need thereof.

1 **32.** A method for treating an individual suffering from or susceptible to a
2 disease or disorder involving pathologic activation of C5a receptors, comprising administering to
3 the individual an effective amount of an amorphous form of Compound 1 according to any one
4 of claims **1** to **15**.

1 **33.** The method of claim **32**, wherein the disease or disorder is an
2 inflammatory disease or disorder.

1 **34.** The method of claim **33**, wherein the disease or disorder is selected from
2 the group consisting of neutropenia, sepsis, septic shock, Alzheimer's disease, multiple sclerosis,
3 stroke, inflammatory bowel disease, age-related macular degeneration, chronic obstructive

4 pulmonary disorder, inflammation associated with burns, lung injury, osteoarthritis, atopic
5 dermatitis, chronic urticaria, ischemia-reperfusion injury, acute respiratory distress syndrome,
6 systemic inflammatory response syndrome, multiple organ dysfunction syndrome, tissue graft
7 rejection, cancer and hyperacute rejection of transplanted organs.

1 **35.** The method of claim **32**, wherein the disease or disorder is a
2 cardiovascular or cerebrovascular disorder.

1 **36.** The method of claim **35**, wherein the disease or disorder is selected from
2 the group consisting of myocardial infarction, coronary thrombosis, vascular occlusion, post-
3 surgical vascular reocclusion, atherosclerosis, traumatic central nervous system injury and
4 ischemic heart disease.

1 **37.** The method of claim **32**, wherein the disease or disorder is an autoimmune
2 disorder.

1 **38.** The method of claim **37**, wherein the disease or disorder is selected from
2 the group consisting of rheumatoid arthritis, C3 glomerulopathy (C3G), hidradenitis suppurativa
3 (HS), systemic lupus erythematosus, Guillain-Barre syndrome, pancreatitis, lupus nephritis,
4 lupus glomerulonephritis, psoriasis, immunoglobulin A (IgA) nephropathy, Crohn's disease,
5 vasculitis, irritable bowel syndrome, dermatomyositis, multiple sclerosis, bronchial asthma,
6 pemphigus, pemphigoid, scleroderma, myasthenia gravis, autoimmune hemolytic and
7 thrombocytopenic states, Goodpasture's syndrome, immunovascularitis, tissue graft rejection and
8 hyperacute rejection of transplanted organs.

1 **39.** The method of claim **32**, wherein the disease or disorder is a pathologic
2 sequelae associated with the group consisting of insulin-dependent diabetes, mellitus, lupus
3 nephropathy, Heyman nephritis, membranous nephritis, glomerulonephritis, contact sensitivity
4 responses, and inflammation resulting from contact of blood with artificial surfaces.

1 **40.** The method of claim **32**, wherein the disease or disorder is selected from
2 the group consisting of anti-neutrophil cytoplasmic antibody associate (ANCA) vasculitis, C3
3 glomerulopathy, hidradenitis suppurativa, and lupus nephritis.

- 1 **41.** The method of claim **32**, wherein the disease or disorder is anti-neutrophil
2 cytoplasmic antibody associate (ANCA) vasculitis.
- 1 **42.** The method of claim **32**, wherein the disease or disorder is granulomatosis
2 with polyangiitis.
- 1 **43.** The method of claim **32**, wherein the disease or disorder is microscopic
2 polyangiitis.
- 1 **44.** The method of claim **32**, wherein the disease or disorder is C3
2 glomerulopathy.
- 1 **45.** The method of claim **32**, wherein the disease or disorder is hidradenitis
2 suppurativa.
- 1 **46.** The method of claim **32**, wherein the disease or disorder is lupus nephritis
- 1 **47..** The method of any one of claims **32** to **46**, further comprising
2 administering to the individual an effective amount of one or more additional therapeutic agents.
- 1 **48.** The method of claim **47**, wherein the one or more additional therapeutic
2 agent is rituximab.
- 1 **49.** The method of claim **47**, wherein the one or more additional therapeutic
2 agent is cyclophosphamide.